The primary purpose of this study is to learn what happens to levels of MK-6552 in the blood when MK-6552 is given in different forms to healthy adult participants under fasted and fed conditions.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
24
Oral Administration
QPS-MRA, LLC-Early Phase ( Site 0001)
South Miami, Florida, United States
Area Under the Plasma Concentration-Time Curve from Time 0 to Last Quantifiable Concentration (AUC0-last) of MK-6552 in a Fasted State
Blood samples will be collected to determine the AUC0-last of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of MK-6552 in a Fasted State
Blood samples will be collected to determine the AUC0-inf of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
Maximum Concentration (Cmax) of MK-6552 in a Fasted State
Blood samples will be collected to determine the Cmax of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
Concentration at 8 hours (C8h) of MK-6552 in a Fasted State
Blood samples will be collected to determine the C8h of MK-6552.
Time frame: 8 hours postdose
Concentration at 16 hours (C16h) of MK-6552 in a Fasted State
Blood samples will be collected to determine the C16h of MK-6552.
Time frame: 16 hours postdose
Time to maximum concentration (Tmax) of MK-6552 in a Fasted State
Blood samples will be collected to determine the Tmax of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
Apparent Terminal Half-life (t1/2) of MK-6552 in a Fasted State
Blood samples will be collected to determine the t1/2 of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
AUC0-last of MK-6552 in a Fed or Fasted State
Blood samples will be collected to determine the AUC0-last of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
AUC0-inf of MK-6552 in a Fed or Fasted State
Blood samples will be collected to determine the AUC0-inf of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
Cmax of MK-6552 in a Fed or Fasted State
Blood samples will be collected to determine the Cmax of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
C8h of MK-6552 in a Fed or Fasted State
Blood samples will be collected to determine the C8h of MK-6552.
Time frame: 8 hours postdose
C16h of MK-6552 in a Fed or Fasted State
Blood samples will be collected to determine the C16h of MK-6552.
Time frame: 16 hours postdose
Tmax of MK-6552 in a Fed or Fasted State
Blood samples will be collected to determine the Tmax of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
t1/2 of MK-6552 in a Fed or Fasted State
Blood samples will be collected to determine the t1/2 of MK-6552.
Time frame: Predose and at designated timepoints approximately up to 3 days postdose
Number of participants with one or more adverse events (AE)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants who experience an AE will be reported.
Time frame: Up to approximately day 35
Number of participants discontinuing from study therapy due to AE
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately day 35